AI Drug Discovery Promises Novel Medicines but Training Data Sets the Limits
AI models learn patterns from compounds, biological data and experimental results that already exist. Therefore, they often perform well when they predict outcomes within familiar chemical space. However, drug discovery becomes harder when researchers ask a model to create a structure with little or no close precedent.
Verseon CEO Adityo Prakash argues that AI handles interpolation better than extrapolation. In practical terms, a model may produce useful variations of known molecules without creating a fundamentally new chemotype. This distinction matters because an output may appear innovative while still depending on familiar structural patterns.
AI Can Predict a New Drug, but It Cannot Validate the Evidence
A computational model can propose a molecule, but it cannot prove that the molecule will work safely or effectively. Scientists must still synthesize the compound, test its binding behaviour and examine its pharmacological properties. Consequently, prediction represents only the beginning of the evidence chain.
Verseon applies this principle across its cardiometabolic and cancer programs. The company designs compounds computationally, produces them in the laboratory and uses the resulting biological data to guide later optimisation. Therefore, experimental evidence remains central to the process.
Verseon Says Physics-Based Drug Design Can Go Where AI Cannot
Verseon calls its platform Deep Quantum Modeling. Instead of asking AI to generate another compound from existing examples, the platform starts with a protein pocket. It then applies molecular and quantum-physics calculations to arrange a potential chemical structure atom by atom.
After laboratory testing creates new evidence, AI helps scientists propose further variations. As a result, Verseon separates molecular creation from AI-led optimisation. This approach does not remove development risk. However, it challenges the assumption that larger datasets alone can solve the chemical novelty problem.
Why GxP Teams Need Stronger Controls for AI Drug Discovery
The debate extends beyond research productivity. As AI enters regulated pharmaceutical workflows, quality and validation teams must understand each system’s intended use, data sources, operating limits and decision pathway. Moreover, they must determine whether another qualified team can reproduce and defend the result.
Weak traceability creates risk when teams cannot explain why a model selected a compound or how input changes affected its output. In addition, uncontrolled model updates may alter performance after initial validation. Pharma companies therefore need lifecycle controls, documented human review and clear links between computational predictions and experimental results.
AI-Designed Molecules Still Face Pharma’s Hardest Test: Real-World Evidence
Verseon’s argument does not reject AI. Instead, it defines a more controlled role for the technology. AI can identify patterns, support optimisation and accelerate scientific decisions. Nevertheless, researchers must test every critical prediction, especially when a model moves beyond chemical patterns that already appear in its training data.
For regulated pharma, novelty alone cannot establish reliability. Companies need reproducible experiments, controlled data and documented decisions that support every scientific claim.
Zaman Pharma’s Qualification and Validation for GMP-Regulated Systems service helps pharmaceutical teams implement and maintain controlled, compliant systems throughout the full lifecycle. Explore how practical validation support can strengthen traceability, system reliability and inspection readiness as AI becomes part of regulated pharmaceutical operations.
Source: Drugdiscoverytrends.Com